

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/002810

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K16/00 A61K39/395

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, MEDLINE, Sequence Search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>TOUT N L ET AL: "Phage display and bacterial expression of a recombinant Fab specific for <i>Pseudomonas aeruginosa</i> serotype O6 lipopolysaccharide" CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 4, no. 2, March 1997 (1997-03), pages 147-155, XP002258884 ISSN: 1071-412X abstract page 152, right-hand column, paragraph 3 - page 153, left-hand column, paragraph 1 ----- -/-</p>	1-11, 28-37

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

20 January 2005

Date of mailing of the international search report

14/02/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Niebuhr-Ebel, K

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB2004/002810

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KHAWLI LESLIE A ET AL: "Stable, genetically engineered F(ab')2 fragments of chimeric TNT-3 expressed in mammalian cells" HYBRIDOMA AND HYBRIDOMICS, vol. 21, no. 1, February 2002 (2002-02), pages 11-18, XP002314088 ISSN: 1536-8599 abstract page 12, right-hand column, paragraph 1 - paragraph 3 page 13, right-hand column, last paragraph - page 14, left-hand column, paragraph 1 -----	1-11, 28-37
X	CHAPMAN A P ET AL: "THERAPEUTIC ANTIBODY FRAGMENTS WITH PROLONGED IN VIVO HALF-LIVES" NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 17, no. 8, August 1999 (1999-08), pages 780-783, XP001199462 ISSN: 1087-0156 page 780, right-hand column, last paragraph - page 782, left-hand column, paragraph 1 -----	12-27
X	LEONG STEVEN R ET AL: "Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation" CYTOKINE, vol. 16, no. 3, 7 November 2001 (2001-11-07), pages 106-119, XP002314089 ISSN: 1043-4666 abstract page 112, right-hand column, paragraph 2 -----	12-27
A	WO 98/25971 A (CELLTECH THERAPEUTICS LTD ; CHAPMAN ANDREW PAUL (GB); KING DAVID JOHN) 18 June 1998 (1998-06-18) "MONOVALENT ANTIBODY FRAGMENTS" page 2, line 25 - page 4, line 5 -----	1-37

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/002810

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9825971	A	18-06-1998	AT 239040 T	15-05-2003
			AU 733251 B2	10-05-2001
			AU 5404998 A	03-07-1998
			CA 2269115 A1	18-06-1998
			DE 69721564 D1	05-06-2003
			DE 69721564 T2	26-02-2004
			DK 948544 T3	04-08-2003
			EP 1160255 A1	05-12-2001
			EP 0948544 A1	13-10-1999
			ES 2197373 T3	01-01-2004
			WO 9825971 A1	18-06-1998
			GB 2334957 A , B	08-09-1999
			JP 3497175 B2	16-02-2004
			JP 2001506990 T	29-05-2001
			NZ 335689 A	24-11-2000
			PT 948544 T	30-09-2003
			US 2004121415 A1	24-06-2004